Colesevelam hydrochloride: Usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol

Alberto Corsini, Eberhard Windler, Michel Farnier

Research output: Contribution to journalArticle

Abstract

Several recent meta-analyses of numerous lipid-lowering outcome trials confirm the direct relationship between low-density lipoprotein-cholesterol (LDL-C) lowering and cardiovascular risk reduction. As a consequence, LDL-C goals are continuously being set lower. To achieve lipid lowering, several efficient drugs are available, however, the current pharmacopoeia remains limited for some critical patient situations. Colesevelam hydrochloride is a specifically engineered bile acid sequestrant that features a more favourable tolerability and drug interaction profile than traditional bile acid sequestrants, because of a better affinity and binding capacity to bile acids. In addition, colesevelam retains the nonsystemic mode of action of bile acid sequestrants. Moreover, colesevelam lowers LDL-C by 15-19% and 10-16%, respectively, in monotherapy and in combination to various lipid-lowering drugs, such as statins, ezetimibe and fenofibrates. Along with an efficient and sustainable effect on lipid profiles, colesevelam - as other bile acid sequestrants - has been shown to lower the glycosylated haemoglobin HbA1c by 0.5% on average in patients with type 2 diabetes. Overall, colesevelam represents an interesting add-on treatment to be used in high-risk patients with hypercholesterolaemia for whom standard lipid-lowering therapies are not enough or not well tolerated.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalEuropean Journal of Cardiovascular Prevention and Rehabilitation
Volume16
Issue number1
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Bile Acids and Salts
LDL Cholesterol
Lipids
Fenofibrate
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacopoeias
Glycosylated Hemoglobin A
Risk Reduction Behavior
Hypercholesterolemia
Drug Interactions
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Meta-Analysis
Colesevelam Hydrochloride
Therapeutics

Keywords

  • Bile acid sequestrant
  • Cardiovascular disease
  • Colesevelam hydrochloride
  • Lipid lowering
  • Low-density lipoprotein-cholesterol
  • Nonsystemic drug

ASJC Scopus subject areas

  • Medicine(all)
  • Cardiology and Cardiovascular Medicine
  • Epidemiology

Cite this

Colesevelam hydrochloride : Usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. / Corsini, Alberto; Windler, Eberhard; Farnier, Michel.

In: European Journal of Cardiovascular Prevention and Rehabilitation, Vol. 16, No. 1, 02.2009, p. 1-9.

Research output: Contribution to journalArticle

@article{cfb7b6e422db4ccd9cef3346a9f3ac6b,
title = "Colesevelam hydrochloride: Usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol",
abstract = "Several recent meta-analyses of numerous lipid-lowering outcome trials confirm the direct relationship between low-density lipoprotein-cholesterol (LDL-C) lowering and cardiovascular risk reduction. As a consequence, LDL-C goals are continuously being set lower. To achieve lipid lowering, several efficient drugs are available, however, the current pharmacopoeia remains limited for some critical patient situations. Colesevelam hydrochloride is a specifically engineered bile acid sequestrant that features a more favourable tolerability and drug interaction profile than traditional bile acid sequestrants, because of a better affinity and binding capacity to bile acids. In addition, colesevelam retains the nonsystemic mode of action of bile acid sequestrants. Moreover, colesevelam lowers LDL-C by 15-19{\%} and 10-16{\%}, respectively, in monotherapy and in combination to various lipid-lowering drugs, such as statins, ezetimibe and fenofibrates. Along with an efficient and sustainable effect on lipid profiles, colesevelam - as other bile acid sequestrants - has been shown to lower the glycosylated haemoglobin HbA1c by 0.5{\%} on average in patients with type 2 diabetes. Overall, colesevelam represents an interesting add-on treatment to be used in high-risk patients with hypercholesterolaemia for whom standard lipid-lowering therapies are not enough or not well tolerated.",
keywords = "Bile acid sequestrant, Cardiovascular disease, Colesevelam hydrochloride, Lipid lowering, Low-density lipoprotein-cholesterol, Nonsystemic drug",
author = "Alberto Corsini and Eberhard Windler and Michel Farnier",
year = "2009",
month = "2",
doi = "10.1097/HJR.0b013e32831215db",
language = "English",
volume = "16",
pages = "1--9",
journal = "European Journal of Cardiovascular Prevention and Rehabilitation",
issn = "1741-8267",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Colesevelam hydrochloride

T2 - Usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol

AU - Corsini, Alberto

AU - Windler, Eberhard

AU - Farnier, Michel

PY - 2009/2

Y1 - 2009/2

N2 - Several recent meta-analyses of numerous lipid-lowering outcome trials confirm the direct relationship between low-density lipoprotein-cholesterol (LDL-C) lowering and cardiovascular risk reduction. As a consequence, LDL-C goals are continuously being set lower. To achieve lipid lowering, several efficient drugs are available, however, the current pharmacopoeia remains limited for some critical patient situations. Colesevelam hydrochloride is a specifically engineered bile acid sequestrant that features a more favourable tolerability and drug interaction profile than traditional bile acid sequestrants, because of a better affinity and binding capacity to bile acids. In addition, colesevelam retains the nonsystemic mode of action of bile acid sequestrants. Moreover, colesevelam lowers LDL-C by 15-19% and 10-16%, respectively, in monotherapy and in combination to various lipid-lowering drugs, such as statins, ezetimibe and fenofibrates. Along with an efficient and sustainable effect on lipid profiles, colesevelam - as other bile acid sequestrants - has been shown to lower the glycosylated haemoglobin HbA1c by 0.5% on average in patients with type 2 diabetes. Overall, colesevelam represents an interesting add-on treatment to be used in high-risk patients with hypercholesterolaemia for whom standard lipid-lowering therapies are not enough or not well tolerated.

AB - Several recent meta-analyses of numerous lipid-lowering outcome trials confirm the direct relationship between low-density lipoprotein-cholesterol (LDL-C) lowering and cardiovascular risk reduction. As a consequence, LDL-C goals are continuously being set lower. To achieve lipid lowering, several efficient drugs are available, however, the current pharmacopoeia remains limited for some critical patient situations. Colesevelam hydrochloride is a specifically engineered bile acid sequestrant that features a more favourable tolerability and drug interaction profile than traditional bile acid sequestrants, because of a better affinity and binding capacity to bile acids. In addition, colesevelam retains the nonsystemic mode of action of bile acid sequestrants. Moreover, colesevelam lowers LDL-C by 15-19% and 10-16%, respectively, in monotherapy and in combination to various lipid-lowering drugs, such as statins, ezetimibe and fenofibrates. Along with an efficient and sustainable effect on lipid profiles, colesevelam - as other bile acid sequestrants - has been shown to lower the glycosylated haemoglobin HbA1c by 0.5% on average in patients with type 2 diabetes. Overall, colesevelam represents an interesting add-on treatment to be used in high-risk patients with hypercholesterolaemia for whom standard lipid-lowering therapies are not enough or not well tolerated.

KW - Bile acid sequestrant

KW - Cardiovascular disease

KW - Colesevelam hydrochloride

KW - Lipid lowering

KW - Low-density lipoprotein-cholesterol

KW - Nonsystemic drug

UR - http://www.scopus.com/inward/record.url?scp=65649114360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649114360&partnerID=8YFLogxK

U2 - 10.1097/HJR.0b013e32831215db

DO - 10.1097/HJR.0b013e32831215db

M3 - Article

C2 - 19237992

AN - SCOPUS:65649114360

VL - 16

SP - 1

EP - 9

JO - European Journal of Cardiovascular Prevention and Rehabilitation

JF - European Journal of Cardiovascular Prevention and Rehabilitation

SN - 1741-8267

IS - 1

ER -